These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
190 related articles for article (PubMed ID: 29704509)
1. Free fatty acid receptor 1 as a novel therapeutic target for type 2 diabetes mellitus-current status. Eleazu C; Charles A; Eleazu K; Achi N Chem Biol Interact; 2018 Jun; 289():32-39. PubMed ID: 29704509 [TBL] [Abstract][Full Text] [Related]
2. Recent Updates on Free Fatty Acid Receptor 1 (GPR-40) Agonists for the Treatment of Type 2 Diabetes Mellitus. Rani L; Grewal AS; Sharma N; Singh S Mini Rev Med Chem; 2021; 21(4):426-470. PubMed ID: 33100202 [TBL] [Abstract][Full Text] [Related]
3. Suppression of free fatty acid receptor 1 expression in pancreatic β-cells in obese type 2 diabetic db/db mice: a potential role of pancreatic and duodenal homeobox factor 1. Kohara K; Obata A; Kimura T; Shimoda M; Moriuchi S; Okauchi S; Hirukawa H; Mune T; Kaku K; Kaneto H Endocr J; 2019 Jan; 66(1):43-50. PubMed ID: 30333365 [TBL] [Abstract][Full Text] [Related]
4. Free Fatty Acid Receptor 1 (FFAR1) as an Emerging Therapeutic Target for Type 2 Diabetes Mellitus: Recent Progress and Prevailing Challenges. Li Z; Xu X; Huang W; Qian H Med Res Rev; 2018 Mar; 38(2):381-425. PubMed ID: 28328012 [TBL] [Abstract][Full Text] [Related]
5. 20-HETE promotes glucose-stimulated insulin secretion in an autocrine manner through FFAR1. Tunaru S; Bonnavion R; Brandenburger I; Preussner J; Thomas D; Scholich K; Offermanns S Nat Commun; 2018 Jan; 9(1):177. PubMed ID: 29330456 [TBL] [Abstract][Full Text] [Related]
6. GPR40: a therapeutic target for mediating insulin secretion (review). Feng XT; Leng J; Xie Z; Li SL; Zhao W; Tang QL Int J Mol Med; 2012 Dec; 30(6):1261-6. PubMed ID: 23023155 [TBL] [Abstract][Full Text] [Related]
7. Point mutation of Ffar1 abrogates fatty acid-dependent insulin secretion, but protects against HFD-induced glucose intolerance. Sabrautzki S; Kaiser G; Przemeck GKH; Gerst F; Lorza-Gil E; Panse M; Sartorius T; Hoene M; Marschall S; Häring HU; Hrabě de Angelis M; Ullrich S Mol Metab; 2017 Oct; 6(10):1304-1312. PubMed ID: 29031729 [TBL] [Abstract][Full Text] [Related]
8. Reevaluation of fatty acid receptor 1 as a drug target for the stimulation of insulin secretion in humans. Wagner R; Kaiser G; Gerst F; Christiansen E; Due-Hansen ME; Grundmann M; Machicao F; Peter A; Kostenis E; Ulven T; Fritsche A; Häring HU; Ullrich S Diabetes; 2013 Jun; 62(6):2106-11. PubMed ID: 23378609 [TBL] [Abstract][Full Text] [Related]
9. A novel antidiabetic drug, fasiglifam/TAK-875, acts as an ago-allosteric modulator of FFAR1. Yabuki C; Komatsu H; Tsujihata Y; Maeda R; Ito R; Matsuda-Nagasumi K; Sakuma K; Miyawaki K; Kikuchi N; Takeuchi K; Habata Y; Mori M PLoS One; 2013; 8(10):e76280. PubMed ID: 24130766 [TBL] [Abstract][Full Text] [Related]
10. Modulating GPR40: therapeutic promise and potential in diabetes. Poitout V; Lin DC Drug Discov Today; 2013 Dec; 18(23-24):1301-8. PubMed ID: 24051395 [TBL] [Abstract][Full Text] [Related]
11. Synthetic GPR40/FFAR1 agonists: An exhaustive survey on the most recent chemical classes and their structure-activity relationships. Paul A; Nahar S; Nahata P; Sarkar A; Maji A; Samanta A; Karmakar S; Maity TK Eur J Med Chem; 2024 Jan; 264():115990. PubMed ID: 38039791 [TBL] [Abstract][Full Text] [Related]
12. Current status of GPR40/FFAR1 modulators in medicinal chemistry (2016-2019): a patent review. Li Z; Zhou Z; Zhang L Expert Opin Ther Pat; 2020 Jan; 30(1):27-38. PubMed ID: 31771391 [No Abstract] [Full Text] [Related]
13. Physiology and therapeutics of the free fatty acid receptor GPR40. Huang H; Dai MH; Tao YX Prog Mol Biol Transl Sci; 2014; 121():67-94. PubMed ID: 24373235 [TBL] [Abstract][Full Text] [Related]
14. G-protein-coupled receptor 40 (GPR40) expression and its regulation in human pancreatic islets: the role of type 2 diabetes and fatty acids. Del Guerra S; Bugliani M; D'Aleo V; Del Prato S; Boggi U; Mosca F; Filipponi F; Lupi R Nutr Metab Cardiovasc Dis; 2010 Jan; 20(1):22-5. PubMed ID: 19758793 [TBL] [Abstract][Full Text] [Related]
15. Free fatty acid receptor 1: a ray of hope in the therapy of type 2 diabetes mellitus. Arora A; Behl T; Sehgal A; Singh S; Sharma N; Chigurupati S; Kaur R; Bhatia S; Al-Harrasi A; Vargas-De-La-Cruz C; Bungau S Inflammopharmacology; 2021 Dec; 29(6):1625-1639. PubMed ID: 34669065 [TBL] [Abstract][Full Text] [Related]
16. Increased glucose metabolism and glycerolipid formation by fatty acids and GPR40 receptor signaling underlies the fatty acid potentiation of insulin secretion. El-Azzouny M; Evans CR; Treutelaar MK; Kennedy RT; Burant CF J Biol Chem; 2014 May; 289(19):13575-88. PubMed ID: 24675078 [TBL] [Abstract][Full Text] [Related]
17. Long-term in vitro treatment of INS-1 rat pancreatic β-cells by unsaturated free fatty acids protects cells against gluco- and lipotoxicities via activation of GPR40 receptors. Tuo Y; Feng DD; Wang DF; Sun J; Li SB; Chen C Clin Exp Pharmacol Physiol; 2012 May; 39(5):423-8. PubMed ID: 22332921 [TBL] [Abstract][Full Text] [Related]
18. The fatty acid receptor FFA1/GPR40 a decade later: how much do we know? Mancini AD; Poitout V Trends Endocrinol Metab; 2013 Aug; 24(8):398-407. PubMed ID: 23631851 [TBL] [Abstract][Full Text] [Related]
19. [Free fatty acid receptors and their physiological role in metabolic regulation]. Hirasawa A; Hara T; Ichimura A; Tsujimoto G Yakugaku Zasshi; 2011; 131(12):1683-9. PubMed ID: 22129861 [TBL] [Abstract][Full Text] [Related]
20. Recent Advances in Development of GPR40 Modulators (FFA1/FFAR1): An Emerging Target for Type 2 Diabetes. Sharma N; Bhagat S; Chundawat TS Mini Rev Med Chem; 2017; 17(11):947-958. PubMed ID: 28117025 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]